Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several ...

Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor ...

Novartis and Matchpoint Therapeutics have entered into a partnership worth $1bn to develop oral inhibitors for inflammatory ...

Matchpoint Therapeutics said that it has signed an exclusive option and license agreement with Novartis (NYSE:NVS) to develop ...

We recently published 8 Stocks That Jim Cramer Recently Talked About. Novartis AG (NYSE:NVS) is one of the stocks Jim Cramer ...

Business was booming for Swiss pharma giant Novartis in the second quarter of 2025 with 11% net sales growth riding strong ...

A U.S. federal judge rejected Swiss drugmaker Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from ...

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

SWX:NOVN Earnings and Revenue History July 24th 2025 The Impact Of Unusual Items On Profit. To properly understand Novartis' profit results, we need to consider the US$2.8b expens ...

Avalere Health, a 2025 MM+M Agency 100 honoree, named Rhiannon Meaden, PhD, as head of medical strategy and transformation.

The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” ...